

HELLENIC REPUBLIC
MINISTRY OF HEALTH
National Organisation for Healthcare
Provision (EOPYY)
www.eopyy.gov.gr

**Directorate General: Planning and
Development of Health Services
Directorate for Medicines
Pharmaceutical Policy Department
Info:**
Tel.: 210 6871755 Fax 210 6871792

Postal address: 39, Kifisias Ave.,
15123 Maroussi
Email: d6@eopyy.gov.gr

Athens, 28 September 2012
Ref. No.: 40890

To:

1. EOPYY's Health Units
2. EOPYY's Regional Services
3. EOPYY's Directorate for Medicines and Pharmacies
4. Prescription Data Processing System (KMES)
5. Social Security e-Government (HDIKA) S.A.
6. Panhellenic Association of Pharmacists
7. Panhellenic Medical Association

Cc.:

1. Minister of Health, Mr Andreas Lykourantzou;
2. Alternate Minister of Health, Mr Marios Salmas;
3. President of EOPYY, Mr Gerasimos Voudouris;
4. Vice-President of EOPYY, Mr Konstantinos Nikolis

Subject: "**Guidance on e-Prescribing**"

Re: 1. Law 4052/2012 (Government Gazette 41/A/1 March 2012);
2. Ministerial Decision ΔΥΓ3(α)/οικ.ΓΥ/149 (Government Gazette 545/B/2012).

As is known, under the above provisions, prescribing by active substance has become mandatory.

We hereby inform you that the relevant department of EOF has prepared a list with the medicinal products which correspond to each active substance, are included in the positive list of drugs and are reimbursed by social security funds. The list also includes reference prices for each active substance, per pharmaceutical form and strength.

As from 1 October 2012, medicinal products in these categories will be reimbursed by EOPYY at the reference price for their respective category.

At present, according to the plan for the implementation of e-prescribing, physicians have the option, once they have determined the active substance, to prescribe any of the corresponding medicinal products. If they prescribe a medicinal product with a higher price than the reference price in its category, they must make clear to the patient that, in addition to the statutory co-payment rate, he/she will be charged with the difference between the retail price of the medicinal product and the reference price.

A message on the printed slip of the electronic prescription will indicate the amount of the additional cost to the insured due to the prescription of a medicine in excess of the reference price, plus the amount of the statutory patient co-payment.

The pharmacist will dispense normally the prescription through the electronic system, as provided for by legislation. The withholding of the additional amount shall be effected automatically by the system, so that the pharmacist will receive from the insured the statutory co-payment plus any difference between the retail price and the reference price.

Gerasimos Voudouris

President of EOPYY